UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000023129
Receipt number R000026148
Scientific Title Sentinel lymph node detection using radioisotopes in skin cancer
Date of disclosure of the study information 2016/07/12
Last modified on 2019/07/15 12:47:59

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Sentinel lymph node detection using radioisotopes in skin cancer

Acronym

Sentinel lymph node detection in skin cancer

Scientific Title

Sentinel lymph node detection using radioisotopes in skin cancer

Scientific Title:Acronym

Sentinel lymph node detection in skin cancer

Region

Japan


Condition

Condition

metastatic skin cancer

Classification by specialty

Dermatology Radiology Plastic surgery
Not applicable

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Study of the significance of sentinel lymph node search inmetastatic skin cancer

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Explanatory

Developmental phase

Not applicable


Assessment

Primary outcomes

Identification and localization of sentinel lymph nodes

Key secondary outcomes

Decision of the cut-off value of lymphatic transit rate
indicating negative nodal metastasis


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Self control

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

No need to know


Intervention

No. of arms

1

Purpose of intervention

Diagnosis

Type of intervention

Medicine

Interventions/Control_1

Intracutaneous injections of Technetium-99m-phytate
(6x18.5MBq) around the tumor at lymphoscintigraphy

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Patients who were diagnosed with metastatic skin cancer based on histopathological examination.

2. From the results of medical history, physical findings, blood, examination, and urine test, the patients who had no serious complications that could not put them under general anesthesia or lumbar anesthesia.

3. Patients who gave written informed consent.

Key exclusion criteria

1. Patients who are pregnant. Patients who are breast-feeding. Patients with drug allergy to Technetium-99m
-phytate.

2. Patients who did not give written informed consent.

3. Attending physician judged that the patients were inappropriate to participate in the study.

Target sample size

240


Research contact person

Name of lead principal investigator

1st name Masao
Middle name
Last name Fujiwara

Organization

Hamamatsu University School of Medicine

Division name

Plastic and Reconstructive Surgery

Zip code

431-3192

Address

1-20-1 Handayama, Hamamatsu, Shizuoka 431-3192

TEL

053-435-2798

Email

jufoasam@hama-med.ac.jp


Public contact

Name of contact person

1st name Masao
Middle name
Last name Fujiwara

Organization

Hamamatsu University School of Medicine

Division name

Plastic and Reconstructive Surgery

Zip code

431-3192

Address

1-20-1 Handayama, Hamamatsu, Shizuoka 431-3192

TEL

053-435-2798

Homepage URL


Email

jufoasam@hama-med.ac.jp


Sponsor or person

Institute

Hamamatsu University School of Medicine

Institute

Department

Personal name



Funding Source

Organization

The Japan Society for the Promotion of Science

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Hamamatsu University School of Medicine

Address

1-20-1 Handayama, Hamamatsu, Shizuoka 431-3192, Japan

Tel

053-435-2680, 2972

Email

rinri@hama-med.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

浜松医科大学医学部附属病院


Other administrative information

Date of disclosure of the study information

2016 Year 07 Month 12 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2016 Year 07 Month 12 Day

Date of IRB

2016 Year 07 Month 05 Day

Anticipated trial start date

2022 Year 03 Month 31 Day

Last follow-up date

2022 Year 07 Month 31 Day

Date of closure to data entry

2023 Year 03 Month 31 Day

Date trial data considered complete

2023 Year 03 Month 31 Day

Date analysis concluded

2023 Year 03 Month 31 Day


Other

Other related information



Management information

Registered date

2016 Year 07 Month 12 Day

Last modified on

2019 Year 07 Month 15 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026148


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name